
X
‘Trojan horse’ cancer drug shows promise in multiple tumour types
https://pharmaphorum.com/news/trojan-horse-cancer-drug-shows-promise-multiple-tumour-types/
Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.
A review of Cancer Research UK’s Grand Challenge awards programme for the latest cancer research projects.
Data gathered from Patient Derived Xenografts will aid drug and biomarker discovery.